# US 2008/0188819 A1 · Beaded Wound Spacer Device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188819 A1
- Document ID: US20080188819A1
- Status: Published application
- Kind: A1
- Application number: 11/774,495
- Filed: 2007-07-06
- Published: 2008-08-07
- Earliest claimed: 2006-07-07
- Assignees: SurModics, Inc.
- Inventors: Tim M. Kloke; Steven J. Keough; Nathan Lockwood; Margaret R. Gardner
- Web page: https://patentgrep.com/patent/US20080188819A1

## CPC

- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61L 17/005: {containing a biologically active substance, e.g. a medicament or a biocide}
- A61L 27/34: Macromolecular materials
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 31/10: Macromolecular materials
- A61P 31/04: Antibacterial agents
- A61L 2300/406: Antibiotics
- A61L 2300/62: Encapsulated active agents, e.g. emulsified droplets
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A wound spacer device comprising multiple beads connected by non-absorbable suture material is disclosed. The device can be applied, for example, by a first responder to an injured individual, or can be applied by a trauma treatment facility, such as a Level 2 medical unit. In typical embodiments the device allows for site-specific controlled elution of an antimicrobial agent, such as Tobramycin, including defined elution over a period of time, such as 48 or 72 hours.

## Claims

### Claim at position 1

1-96. (canceled)

### Claim 97

A removable wound spacer packing device, said wound spacer packing device comprising:
a plurality of beads arranged along a flexible polyamide connector material, each of said beads comprising:
a polyamide core;
a first layer outside said core, said first layer containing a bioactive agent and a polymeric material derived from poly[vinylpyrrolidone];
a second layer outside said first layer, said second layer comprising poly(butylmethacrylate) and poly(ethylene-co-vinyl acetate);
a third layer outside said first layer, said third layer comprising poly(butylmethacrylate).

### Claim 98 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the second layer further comprises poly(vinylpyrrolidone).

### Claim 99 (depends on 98)

The removable wound spacer packing device of claim 98, wherein the second layer further comprises photoreagent tetrakis (4-benzophenylmethoxymethyl)methane.

### Claim 100 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the bioactive agent is selected from the group consisting of tobramycin, tobramycin sulfate, vancomycin, amikacin, gentamicin, kanamycin, neomycin, tigecycline, netilmicin, paromomycin, streptomycin, and apramycin and combinations thereof.

### Claim 101 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the bioactive agent comprises tobramycin sulfate.

### Claim 102 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the poly(ethylene-co-vinyl acetate) is selected from the group consisting of poly(ethylene-co-vinyl acetate) polymers having vinyl acetate concentrations of between about 10% and about 50% by weight.

### Claim 103 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the bioactive agent comprises a dose of about 500 to 2000 mcg per bead.

### Claim 104 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the bioactive agent has an elution profile such that at least 50 percent of the bioactive agent releases from the first, second, and third layers within 72 hours of placement within a wound.

### Claim 105 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the bioactive agent has an elution profile such that at least 65 percent of the bioactive agent releases from the first, second, and third layers within 72 hours of placement within a wound.

### Claim 106 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the beads are each molded to the connector material with sufficient strength so that the connector material will break under a tension load before the bond between the connector material and polyamide core breaks.

### Claim 107 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the cores of the plurality of beads contain barium sulfate.

### Claim 108 (depends on 97)

The removable wound spacer packing device of claim 97, wherein only a portion of each bead of the plurality of beads contains barium sulfate

### Claim 109 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the plurality of beads have an average spacing distance that is between 0.8 and 1.2 times the length of the average bead core diameter in contact with the connecting material.

### Claim 110 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the first layer outside the core is crosslinked.

### Claim 111 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the second layer outside the core is crosslinked to the first layer outside the core.

### Claim 112 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the flexible polyamide connector material is coated with at least a first layer containing a bioactive agent and a polymeric material derived from poly[vinylpyrrolidone].

### Claim 113 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the flexible polyamide connector material is substantially free of silicone.

### Claim 114 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the connector material comprises flexile suture material.

### Claim 115 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the beads are non-spherical.

### Claim 116 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the beads have an average volume between 15 and 8,000 cubic millimeters.

### Claim 117 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the device volume is from 1 to 150 cubic centimeters.

### Claim 118 (depends on 97)

The removable wound spacer packing device of claim 97, wherein the minimum occupied volume of the device is at least 1.25 times the volume of the device itself.

### Claim 119

A removable wound spacer packing device, said wound spacer packing device comprising:
a plurality of beads arranged along a flexible polyamide connector material, each of said polyamide beads comprising:
a polyamide core containing barium sulfate;
a first layer outside said core, said first layer containing a bioactive agent and a polymeric material derived from poly[vinylpyrrolidone];
a second layer outside said first layer, said second layer comprising a material derived from poly(butylmethacrylate), poly(ethylene-co-vinyl acetate), poly(vinyl pyrrolidone), and tetrakis(4-benzophenylmethoxymethyl)methane; and
a third layer outside said first layer, said third layer comprising poly(butylmethacrylate).

### Claim 120 (depends on 119)

The removable wound spacer packing device of claim 119, wherein the bioactive agent is selected from the group consisting of tobramycin, tobramycin sulfate, vancomycin, amikacin, gentamicin, kanamycin, neomycin, tigecycline, netilmicin, paromomycin, streptomycin, and apramycin and combinations thereof.

### Claim 121 (depends on 119)

The removable wound spacer packing device of claim 119, wherein the bioactive agent has an elution profile such that at least 65 percent of the bioactive agent elutes within 72 hours of placement within a wound.

### Claim 122 (depends on 119)

The removable wound spacer packing device of claim 119, wherein the poly(ethylene-co-vinyl acetate) is selected from the group consisting of poly(ethylene-co-vinyl acetate) polymers having vinyl acetate concentrations of between about 10% and about 50% by weight.

### Claim 123 (depends on 119)

The removable wound spacer packing device of claim 119, wherein the flexible polyamide connector material is coated with at least a first layer containing a bioactive agent and a polymeric material derived from poly[vinylpyrrolidone].

### Claim 124

A kit for treating a wound, the kit comprising:
at least two removable wound spacer packing devices, each of said wound spacer packing devices comprising a plurality of beads arranged along a flexible polyamide connector material, each of said polyamide beads comprising:
a polyamide core containing barium sulfate;
a first layer outside said core, said first layer containing a bioactive agent and a polymeric material derived from poly[vinylpyrrolidone];
a second layer outside said first layer, said second layer comprising a material derived from poly(butylmethacrylate), poly(ethylene-co-vinyl acetate), poly(vinyl pyrrolidone), and tetrakis(4-benzophenylmethoxymethyl)methane; and
a third layer outside said first layer, said third layer comprising poly(butylmethacrylate); and
a retaining device for holding the at least two removable wound spacer packing devices during storage and prior to application to a wound.

### Claim 125 (depends on 124)

The kit for treating a wound of claim 124, wherein at least one of the wound spacer packing devices contains the bioactive agent tobramycin sulfate.

### Claim 126 (depends on 125)

The kit for treating a wound of claim 125, wherein at least one of the wound spacer packing devices contains a gram positive bioactive agent.
